1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Alnylam Acquires Sirna Therapeutics

M&A Deal Summary

Alnylam Acquires Sirna Therapeutics

On March 5, 2014, Alnylam acquired life science company Sirna Therapeutics

Acquisition Highlights
  • This is Alnylam’s 1st transaction in the Life Science sector.
  • This is Alnylam’s 1st transaction in the United States.
  • This is Alnylam’s 1st transaction in California.

M&A Deal Summary
Date 2014-03-05
Target Sirna Therapeutics
Sector Life Science
Buyer(s) Alnylam
Deal Type Add-on Acquisition

Target

Sirna Therapeutics

San Francisco, California, United States
Sirna Therapeutics, Inc. is a provider of research, preclinical, and/or clinical development with product candidates in various areas, including age-related macular degeneration (AMD).

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alnylam

Cambridge, Massachusetts, United States
Category Company
Founded 2002
Sector Life Science
Employees2,230
Revenue 2.2B USD (2024)
DESCRIPTION

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Alnylam was formed in 2002 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2014 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal